A study published recently in the Journal of Clinical Oncology Precision Oncology, an American Society of Clinical Oncology (ASCO) journal, outlines findings from the largest-ever prospective genomic analysis of advanced prostate cancer tumors. Using comprehensive genomic profiling (CGP) to analyze thousands of tumor samples from men with advanced prostate cancers, the researchers identified that 57% of the samples evaluated had genomic characteristics that suggested the tumors were candidates for targeted therapies.
